Impact of molecular profiles in outcome of prospective randomized trials.
| . | CR . | OR . | PFS . | OS . |
|---|---|---|---|---|
| Abbreviations: CR, complete response; OR, overall response; PFS, progression-free survival; OS, overall survival; FC, fludarabine cyclophosphamide | ||||
| CALGB 971238 | None significant | None significant | IgVH del 11q, del 17p | IgVH del 11q del 17p |
| ECOG 299739 | None significant | None significant | IgVH (for FC only) del 11q, del 17p | Not stated |
| LRF CLL440 | del 11q, del 17p | del 11q, del 17p | IgVH del 11q | Not stated |
| . | CR . | OR . | PFS . | OS . |
|---|---|---|---|---|
| Abbreviations: CR, complete response; OR, overall response; PFS, progression-free survival; OS, overall survival; FC, fludarabine cyclophosphamide | ||||
| CALGB 971238 | None significant | None significant | IgVH del 11q, del 17p | IgVH del 11q del 17p |
| ECOG 299739 | None significant | None significant | IgVH (for FC only) del 11q, del 17p | Not stated |
| LRF CLL440 | del 11q, del 17p | del 11q, del 17p | IgVH del 11q | Not stated |